Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| METTLER TOLEDO INTERNATIONAL INC/MTD · Entity 3168 | Director | November 12, 2024 | November 14, 2024 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | President and CEO | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
METTLER TOLEDO INTERNATIONAL INC/
Report date November 12, 2024 · Filed November 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 624 |
Reported balance
After 2024-11-12 transaction · row 1
1 source rowRow 1 · 2024-11-12 · Grant · Acquired 71 · Balance 624 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,260.97 · Expires 2034-11-12 | Direct | 182 |
Reported balance
After 2024-11-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-12 · Grant · Acquired 182 · Balance 182 F1: The options vest annually in two equal installments beginning on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest annually in two equal installments beginning on the first anniversary of the date of grant.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,177,529 |
Last balance in matching sequence
After 2026-06-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-06-05 · Exercise / conversion · Acquired 13,043 · Balance 1,183,682 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 2 · 2026-06-05 · Sale · Disposed 6,153 · Balance 1,177,529 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025. F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 39,130 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Exercise / conversion · Disposed 13,043 · Balance 39,130 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.
F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F5: Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 13,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-261660 · ownership.xml · derivative · entry 3 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,130 Underlying: Ordinary Shares · 13,043 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029. F5 · derivative.expiration_date: Restricted share units were granted on June 5, 2025, with 13,043 vested on June 5, 2026, 13,043 vesting on each of June 5, 2027 and June 5, 2028, and 13,044 vesting on June 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,153 | $34.35 | $211,355.55 |
DisclosureSEC source: 0001193125-26-261660 · ownership.xml · nonDerivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,177,529 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 13,043 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-261660 · ownership.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,183,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 42,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-098551 · ownership.xml · derivative · entry 3 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,359 Underlying: Ordinary Shares · 42,452 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 42,452 vested on March 5, 2026, 42,452 vesting on each of March 5, 2027 and March 5, 2028, and 42,455 vesting on March 5, 2029. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 42,452 vested on March 5, 2026, 42,452 vesting on each of March 5, 2027 and March 5, 2028, and 42,455 vesting on March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 20,025 | $31.67 | $634,159.71 |
DisclosureSEC source: 0001193125-26-098551 · ownership.xml · nonDerivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,170,639 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:18 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 42,452 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-098551 · ownership.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,190,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 136,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096591 · ownership.xml · derivative · entry 4 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,736 Underlying: Ordinary Shares · 136,736 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 34,184 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 34,184 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 50,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096591 · ownership.xml · derivative · entry 3 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,446 Underlying: Ordinary Shares · 50,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 50,223 vested on each of March 4, 2025 and March 4, 2026, and 50,223 vesting on each of March 4, 2027 and March 4, 2028. F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 50,223 vested on each of March 4, 2025 and March 4, 2026, and 50,223 vesting on each of March 4, 2027 and March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 23,393 | $32.46 | $759,442.05 |
DisclosureSEC source: 0001193125-26-096591 · ownership.xml · nonDerivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,148,212 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 50,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-096591 · ownership.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,171,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 891,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-093916 · ownership.xml · derivative · entry 6 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 891,315 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria. F7 · derivative.expiration_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 67,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-093916 · ownership.xml · derivative · entry 5 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,231 Underlying: Ordinary Shares · 67,231 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 67,231 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 67,231 vesting on March 3, 2027. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 67,231 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 67,231 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 412,032 | $32.36 | $13,333,314.32 |
DisclosureSEC source: 0001193125-26-093916 · ownership.xml · nonDerivative · entry 4 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,121,382 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 891,315 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-093916 · ownership.xml · nonDerivative · entry 3 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,533,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 30,903 | $32.36 | $1,000,017.99 |
DisclosureSEC source: 0001193125-26-093916 · ownership.xml · nonDerivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 642,099 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 67,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-093916 · ownership.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 673,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 620,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-056996 · ownership.xml · derivative · entry 6 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 620,110 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on February 15, 2026, following satisfaction of the time-based vesting criteria. F7 · derivative.expiration_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on February 15, 2026, following satisfaction of the time-based vesting criteria. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 161,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-056996 · ownership.xml · derivative · entry 5 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 161,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 15, 2023, with 161,655 vested on each of February 15, 2024 and February 15, 2025, and 161,656 vested on February 15, 2026. F6 · derivative.expiration_date: Restricted share units were granted on February 15, 2023, with 161,655 vested on each of February 15, 2024 and February 15, 2025, and 161,656 vested on February 15, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 286,122 | $34.22 | $9,792,267.94 |
DisclosureSEC source: 0001193125-26-056996 · ownership.xml · nonDerivative · entry 4 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,771 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025. F4 · shares: Represents (1) with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting, and (2) with respect to the restricted share units granted subject to performance criteria, the reporting person sold such number of shares required to cover tax witholding obligations in connection with the vesting. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.015 to $34.51, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 620,110 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-056996 · ownership.xml · nonDerivative · entry 3 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 891,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 161,656 | $34.22 | $5,532,531.11 |
DisclosureSEC source: 0001193125-26-056996 · ownership.xml · nonDerivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,783 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025. F4 · shares: Represents (1) with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting, and (2) with respect to the restricted share units granted subject to performance criteria, the reporting person sold such number of shares required to cover tax witholding obligations in connection with the vesting. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.015 to $34.51, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 161,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-056996 · ownership.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 433,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 891,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-029300 · ownership.xml · derivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 891,315 Underlying: Ordinary Shares · 891,315 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026. F4 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 620,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-029300 · ownership.xml · derivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 620,110 Underlying: Ordinary Shares · 620,110 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted shares units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 15, 2026. F2 · derivative.expiration_date: Represents restricted shares units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 15, 2026. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 52,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083680 · ownership.xml · derivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,173 Underlying: Ordinary Shares · 52,173 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 5, 2025, with 13,043 vesting on each of June 5, 2026, June 5, 2027, and June 5, 2028 and 13,044 vesting on June 5, 2029. F2 · derivative.expiration_date: Restricted share units were granted on June 5, 2025, with 13,043 vesting on each of June 5, 2026, June 5, 2027, and June 5, 2028 and 13,044 vesting on June 5, 2029. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 8,259 | $15.91 | $131,427.12 |
DisclosureSEC source: 0000950170-25-034583 · ownership.xml · nonDerivative · entry 3 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 271,783 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 169,811 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035467 · ownership.xml · derivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,811 Underlying: Ordinary Shares · 169,811 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 42,452 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 42,455 vesting on March 5, 2029. F2 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 42,452 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 42,455 vesting on March 5, 2029. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,450 | $15.56 | $100,346.52 |
DisclosureSEC source: 0000950170-25-033515 · ownership.xml · nonDerivative · entry 3 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,333 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.455 to $15.75, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 50,223 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034583 · ownership.xml · derivative · entry 4 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,669 Underlying: Ordinary Shares · 50,223 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 50,223 vested on March 4, 2025, and 50,223 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 50,223 vested on March 4, 2025, and 50,223 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 15,514 | $15.73 | $244,106.58 |
DisclosureSEC source: 0000950170-25-034583 · ownership.xml · nonDerivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 280,042 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 50,223 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034583 · ownership.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 295,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 67,231 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033515 · ownership.xml · derivative · entry 4 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,462 Underlying: Ordinary Shares · 67,231 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 67,231 vested on each of March 3, 2024 and March 3, 2025, and 67,231 vesting on each of March 3, 2026 and March 3, 2027. F7 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 67,231 vested on each of March 3, 2024 and March 3, 2025, and 67,231 vesting on each of March 3, 2026 and March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 24,892 | $16.19 | $402,889.47 |
DisclosureSEC source: 0000950170-25-033515 · ownership.xml · nonDerivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 251,783 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.86 to $16.53, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 67,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-033515 · ownership.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 75,506 | $16.95 | $1,279,660.59 |
DisclosureSEC source: 0000950170-25-023126 · ownership.xml · nonDerivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,444 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.885 to $17.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 161,655 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023126 · ownership.xml · derivative · entry 3 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,656 Underlying: Ordinary Shares · 161,655 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 15, 2023 with 161,655 vested on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026. F6 · derivative.expiration_date: Restricted share units were granted on February 15, 2023 with 161,655 vested on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 21:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 161,655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023126 · ownership.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 18:35 UTC | METTLER TOLEDO INTERNATIONAL INC/ MTD · Entity 3168 | GrantStock Option (right to buy) · Derivative | 182 | $0.00 Strike: $1,260.97 | $0.00 |
DisclosureSEC source: 0001062993-24-019115 · form4.xml · derivative · entry 2 Francis Richard D · CIK 0001673277 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182 Underlying: Common Stock, par value $0.01 per share · 182 shares Expires 2034-11-12 F1 · derivative.exercise_date: The options vest annually in two equal installments beginning on the first anniversary of the date of grant. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 18:35 UTC | METTLER TOLEDO INTERNATIONAL INC/ MTD · Entity 3168 | GrantCommon Stock, par value $0.01 per share | 71 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-019115 · form4.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 624 Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:27 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 200,892 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026008 · ownership.xml · derivative · entry 4 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,892 Underlying: Ordinary Shares · 200,892 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 50,223 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027 and March 4, 2028. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 50,223 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027 and March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:27 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 31,061 | $13.34 | $414,269.88 |
DisclosureSEC source: 0000950170-24-026008 · ownership.xml · nonDerivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,295 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:27 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 67,231 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026008 · ownership.xml · derivative · entry 3 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,693 Underlying: Ordinary Shares · 67,231 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 67,231 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 67,231 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2024 Filed Mar 5, 2024 21:27 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 67,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-026008 · ownership.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 12:42 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 161,655 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016803 · ownership.xml · derivative · entry 3 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 323,311 Underlying: Ordinary Shares · 161,655 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026. F6 · derivative.expiration_date: Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 12:42 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 74,530 | $13.15 | $980,173.84 |
DisclosureSEC source: 0000950170-24-016803 · ownership.xml · nonDerivative · entry 2 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,125 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.09 to $13.24, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 12:42 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 161,655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016803 · ownership.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 13:45 UTC | METTLER TOLEDO INTERNATIONAL INC/ MTD · Entity 3168 | GrantStock Option (right to buy) · Derivative | 250 | $0.00 Strike: $1,024.55 | $0.00 |
DisclosureSEC source: 0001062993-23-020526 · form4.xml · derivative · entry 2 Francis Richard D · CIK 0001673277 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250 Underlying: Common Stock, par value $0.01 per share · 250 shares Expires 2033-11-09 F1 · derivative.exercise_date: The options vest annually in two equal installments beginning on the first anniversary of the date of grant. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 13:45 UTC | METTLER TOLEDO INTERNATIONAL INC/ MTD · Entity 3168 | GrantCommon Stock, par value $0.01 per share | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020526 · form4.xml · nonDerivative · entry 1 Francis Richard D · CIK 0001673277 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 553 Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 268,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016701 · doc4.xml · derivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,924 Underlying: Ordinary Shares · 268,924 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 67,231 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027. F2 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 67,231 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 12:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 484,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010333 · doc4.xml · derivative · entry 1 Francis Richard D · CIK 0001673277 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,966 Underlying: Ordinary Shares · 484,966 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026. F2 · derivative.expiration_date: Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.